Three START Midwest clinical trials were presented last week at the Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting, which took place virtually. START Midwest physicians Nehal Lakhani, MD, PhD, and Manish Sharma, MD, were both credited as authors of abstracts submitted. All abstracts have now been published on the Journal for ImmunoTherapy of Cancer’s website and can be found below:
- “404 ALX148, a CD47 blocker, in combination with standard chemotherapy and antibody regimens in patients with gastric/gastroesophageal junction (GC) cancer and head and neck squamous cell carcinoma (HNSCC)” (Dr. Nehal Lakhani)
- “295 First-in-human Phase I trial of IBI188, an anti-CD47 targeting monoclonal antibody, in patients with advanced solid tumors and lymphomas” (Dr. Nehal Lakhani)
- 401 Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors (Dr. Manish Sharma)
Contact Information
Becky Downing, Social Media & Marketing Specialist
bdowning@chcwm.com